Madhu Kumar
Stock Analyst at Goldman Sachs
(3.63)
# 924
Out of 4,667 analysts
156
Total ratings
56.44%
Success rate
19.6%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $116.82 | +44.67% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $3.01 | +99.34% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $25.74 | +1.01% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $16.59 | +2.47% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $3.85 | +3.90% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $177.85 | -12.85% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $51.09 | +3.74% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $5.48 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $18.60 | +292.47% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $28.99 | +386.37% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $15.77 | +115.60% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $8.19 | -26.74% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $18.06 | -22.48% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $12.01 | +74.85% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $31.51 | -84.13% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.48 | +222.58% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $21.64 | +311.28% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.48 | +1,144.81% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $8.93 | +11.98% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $14.13 | +501.56% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.96 | +1,889.80% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $5.82 | +879.38% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.49 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.02 | +29,701.32% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $6.93 | +188.60% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $400 | $15.59 | +2,465.75% | 3 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.57 | +6,269.43% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $27.86 | +25.63% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $2.70 | +2,122.22% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $9.21 | +334.31% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $15.34 | +3,185.53% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $234.27 | -1.82% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $1.42 | +4,125.35% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.92 | +1,983.33% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $30.32 | -29.09% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $46.97 | -49.97% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $116.82
Upside: +44.67%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $3.01
Upside: +99.34%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $25.74
Upside: +1.01%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $16.59
Upside: +2.47%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $3.85
Upside: +3.90%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $177.85
Upside: -12.85%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $51.09
Upside: +3.74%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $5.48
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $18.60
Upside: +292.47%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $28.99
Upside: +386.37%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $15.77
Upside: +115.60%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $8.19
Upside: -26.74%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $18.06
Upside: -22.48%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $12.01
Upside: +74.85%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $31.51
Upside: -84.13%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.48
Upside: +222.58%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $21.64
Upside: +311.28%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.48
Upside: +1,144.81%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $8.93
Upside: +11.98%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $14.13
Upside: +501.56%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.96
Upside: +1,889.80%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $5.82
Upside: +879.38%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.49
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $3.02
Upside: +29,701.32%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $6.93
Upside: +188.60%
Mar 13, 2020
Upgrades: Outperform
Price Target: $400
Current: $15.59
Upside: +2,465.75%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.57
Upside: +6,269.43%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $27.86
Upside: +25.63%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $2.70
Upside: +2,122.22%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $9.21
Upside: +334.31%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $15.34
Upside: +3,185.53%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $234.27
Upside: -1.82%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $1.42
Upside: +4,125.35%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.92
Upside: +1,983.33%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $30.32
Upside: -29.09%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $46.97
Upside: -49.97%